MedTrace Logo

A Study on Association Between HR Genes and the HRD Status in Chinese Epithelial Ovarian Cancer

NCT04651920 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2022-03-29

No results posted yet for this study

Summary

The association between homologous recombination (HR) gene mutations and homologous recombination deficiency (HRD) status in Chinese epithelial ovarian cancer (EOC) patients is little known. This study would recruit 400 Chinese EOC patients with known targeted gene mutations via a multi-panel testing of 27 genes, including BRCA1/BRCA2. All patients accept evaluation of HRD model, which is based on the loss of heterozygosity (LOH), telomere allele imbalance (TAI) and large-scale state transitions (LST). The mutated genes, HRD score model and their relationship with the prognosis, would provide a full description of for the Chinese EOC patients, and a potential explanation of platinum-resistance in such population.

Conditions

  • Epithelial Ovarian Cancer
  • Chinese
  • Homologous Recombination Deficiency
  • BRCA1 Mutation
  • BRCA2 Mutation
  • Prognosis
  • Homologous Recombination Genes

Interventions

GENETIC

Evaluation of homologous recombination deficiency score

Evaluation of homologous recombination deficiency score which is based on the loss of heterozygosity (LOH), telomere allele imbalance (TAI) and large-scale state transitions (LST)

Sponsors & Collaborators

  • Lei Li

    lead OTHER

Principal Investigators

  • Lei Li, M.D. · Peking Union Medical College Hospital

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-26
Primary Completion
2022-03-26
Completion
2022-03-26

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04651920 on ClinicalTrials.gov